Provided by Tiger Trade Technology Pte. Ltd.

ASCLETIS-B

10.020
-0.080-0.79%
Volume:2.08M
Turnover:20.50M
Market Cap:10.54B
PE:-27.07
High:10.020
Open:9.965
Low:9.515
Close:10.100
52wk High:19.860
52wk Low:7.950
Shares:1.05B
HK Float Shares:1.05B
Volume Ratio:1.27
T/O Rate:0.20%
Dividend:- -
Dividend Rate:- -
EPS(LYR):-0.370
ROE:-18.45%
ROA:-14.45%
PB:4.67
PE(LYR):-27.07
PS:4455.19

Loading ...

Ascletis Launches U.S. Phase I Trials for Potential First-in-Class Monthly Obesity Injections ASC36 and ASC36_35FDC

Bulletin Express
·
Aug 10

Ascletis Announces Initiation of Two Phase I Studies in U.S. for the Treatment of Obesity: Asc36 Once-Monthly Injection, an Amylin Receptor Peptide Agonist, and Asc36_35Fdc Once-Monthly Injection, a Co-Formulation of Asc36 and Glp-1R/Gipr Peptide Agonist Asc35

THOMSON REUTERS
·
Aug 10

Ascletis-B Launches Two Phase 1 Obesity Studies in the United States

Stock News
·
Aug 10

Ascletis Pharma - U.S. FDA Clears Ind Applications for Asc36 and Asc36_35Fdc

THOMSON REUTERS
·
Aug 10

Ascletis Says FDA Clears INDs for Obesity Candidates Asc36, Asc36_35fdc

Reuters
·
Aug 10

Hong Kong Market Movers: Innovative Drug Stocks Rally as Earnings Season Approaches, Medical Conferences Expected to Provide Catalysts

Stock News
·
Aug 07

Ascletis Pharma Shares Surge 5% on Global Phase 3 Trial Launch for GLP-1 Oral Drug ASC30

Deep News
·
Aug 04

Is Ascletis’ Biologic Obesity Pipeline Altering The Investment Case For Ascletis Pharma (SEHK:1672)?

Simply Wall St.
·
Aug 04

Ascletis Announces Initiation of Global Phase Iii for Oral Small Molecule Glp-1, Asc30 and Positive Preclinical Data for Its First-in-Class Oral Small Molecule Glp-1/Gip/Amylin Fixed-Dose Combination

THOMSON REUTERS
·
Aug 03

Ascletis Pharma - Has Sufficient Cash to Support Operations into 2029

THOMSON REUTERS
·
Aug 03

Ascletis Pharma - Expects Asc30 Phase Iii Topline Data Q3 2028; Nda End 2028; Maa Early 2029

THOMSON REUTERS
·
Aug 03

Ascletis Pharma - Initiates Global Phase Iii for Asc30 in Obesity with 4,600 Participants

THOMSON REUTERS
·
Aug 03

Ascletis Says FDA Clears Phase III Trials for Oral GLP-1 Obesity Drug ASC30

Reuters
·
Aug 03

Ascletis Pharma Schedules Board Meeting to Review Interim Results, Consider Dividend

Reuters
·
Aug 03

Ascletis Pharma Files HKEX Next-day Disclosure Return on Share Repurchase for Cancellation

Reuters
·
Jul 30

ASCLETIS-B (01672) Spends HK$1.76 Million to Buy Back 200,000 Shares on July 29

Stock News
·
Jul 29

Ascletis Pharma - Ind Applications for Asc37 Sq and Oral Formulations to be Submitted in Q3 2026

THOMSON REUTERS
·
Jul 27

Ascletis Announces Once-Monthly Subcutaneously Administered Glp-1R/Gipr/Gcgr Triple Peptide Agonist, Asc37, Demonstrated Superior Weight Loss in a Diet-Induced Obese Mouse Model

THOMSON REUTERS
·
Jul 27

Ascletis Pharma - Announces Asc37 Demonstrates Superior Weight Loss in Obese Mouse Model

THOMSON REUTERS
·
Jul 27

Ascletis’ ASC37 Triple Agonist Delivers 88% Greater Weight Loss Than Tirzepatide; Monthly Injection and Oral BLA Filings Planned for 2026

Bulletin Express
·
Jul 27